LENZ Therapeutics, Inc. (LENZ)
| Market Cap | 932.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -60.81M |
| Shares Out | 27.50M |
| EPS (ttm) | -2.69 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 92,111 |
| Open | 34.43 |
| Previous Close | 34.65 |
| Day's Range | 32.84 - 34.73 |
| 52-Week Range | 2.12 - 38.93 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 35.40 (+4.39%) |
| Earnings Date | Nov 6, 2024 |
About LENZ
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California. [Read more]
Analyst Forecast
According to 6 analysts, the average rating for LENZ stock is "Strong Buy." The 12-month stock price forecast is $35.4, which is an increase of 4.39% from the latest price.
News
LENZ Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commerci...
LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President and CEO Shawn Olsson - CCO...
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships
On Sunday, Corxel Pharmaceuticals and LENZ Therapeutics LENZ released topline data from the Phase 3 JX07001 trial of LNZ100 in patients with presbyopia in China.
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., n...
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025
Lucy Therapeutics Appoints Kim Drapkin as Board Chair
WALTHAM, Mass.--(BUSINESS WIRE)--Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinso...
LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks
Graphite Bio reverse merged with Lenz Therapeutics to focus on presbyopia, a $3bn+ market impacting 1.8 billion people globally. LNZ100, a 1.75% Aceclidine eye drop solution, conducted two positive ph...
LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President & CEO Shawn Olsson - Chief ...
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only...
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidi...
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE N...
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidin...
LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President and CEO Dr....
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidin...
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study
Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the bell.
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop...
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop...
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress
SAN DIEGO--(BUSINESS WIRE)--LENZ Therapeutics, Inc. (Nasdaq: LENZ) (LENZ or the Company), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that...